title: Pneumocystis jiroveci pneumonitis complicating ruxolitinib therapy.
abstract: Ruxolitinib is a novel inhibitor of the Janus kinase (JAK) pathway that has become available for the treatment of myelofibrosis. There are increasing reports of opportunistic infections associated with ruxolitinib therapy. We present a case of Pneumocystis jiroveci pneumonitis complicating ruxolitinib therapy. Clinicians should consider the use of pneumocystis prophylaxis when using ruxolitinib.
authors.affiliation: School of Medicine, University of Queensland, St Lucia, Queensland, Australia.
authors.forename: Samantha C
authors.initials: SC
authors.lastname: Lee
authors.affiliation: School of Medicine, University of Queensland, St Lucia, Queensland, Australia Department of Thoracic Medicine, The Wesley Hospital, Auchenflower, Queensland, Australia.
authors.forename: John
authors.initials: J
authors.lastname: Feenstra
authors.affiliation: Department of Infectious Diseases, The Wesley Hospital, Auchenflower, Queensland, Australia.
authors.forename: Paul R
authors.initials: PR
authors.lastname: Georghiou
mesh_terms: D000368:Aged; D006801:Humans; D016867:Immunocompromised Host; D053612:Janus Kinases / Q000037:antagonists & inhibitors*; D008297:Male; D009570:Nitriles; D045363:Pneumocystis carinii; D011020:Pneumonia, Pneumocystis / Q000209:etiology* / Q000517:prevention & control; D055728:Primary Myelofibrosis / Q000188:drug therapy; D011720:Pyrazoles / Q000009:adverse effects* / Q000627:therapeutic use; D011743:Pyrimidines
chemical_list: D009570:Nitriles; D011720:Pyrazoles; D011743:Pyrimidines; C540383:ruxolitinib; D053612:Janus Kinases